TG Therapeutics’ CFO and CEO Flip Flop: CFO Buys Zero‑Cash Shares, CEO Purchases 622,000 Amid Market Turbulence

Insider Confidence in a Volatile Landscape

On January 8, 2026, TG Therapeutics’ Chief Financial Officer, Sean Power, executed a 90,000‑share purchase of restricted common stock at no cash consideration. The transaction, filed as a “buy” under Form 4, reflects a grant of restricted shares that will vest quarterly over the next four years. While the purchase price is listed as $0.00—typical for equity grants—Power’s decision to acquire additional shares signals continued confidence in the company’s long‑term prospects, even as the stock has recently slipped below its 52‑week low.

CEO Activity Trumps CFO Moves

The same day, CEO Michael Weiss disclosed a substantial purchase of 622,000 shares, bringing his total holdings to nearly 9.8 million. This buy follows a dramatic sell of 3.87 million shares on November 5, 2025, which had previously reduced his stake from 9.96 million to 9.16 million. Weiss’s reversal—from a massive divestiture to a sizeable acquisition—may be interpreted as a signal that he expects the company’s valuation to rebound. The contrast between CFO Power’s restricted‑share grant and CEO Weiss’s open‑market buy illustrates differing liquidity needs and risk appetites within the same leadership team.

Implications for Investors

For investors, the combined insider activity suggests that management believes TG’s pipeline—particularly its hematologic oncology candidates—will eventually yield significant upside. The restricted‑share grant to the CFO aligns with a long‑term commitment, while the CEO’s large purchase immediately after a major sell indicates a belief that the current price underrepresents the company’s intrinsic value. Nonetheless, the stock’s recent decline, coupled with a negative market sentiment score of –87 and a 1,504 % spike in social‑media buzz, points to heightened volatility and speculative pressure. Investors should weigh the insider optimism against the broader market uncertainty and the company’s still‑unrealized clinical milestones.

Strategic Outlook Amidst Volatility

TG Therapeutics trades at a P/E of 10.9 and a P/B of 7.05, reflecting modest earnings expectations but a premium valuation driven by potential growth. The company’s recent participation in the J.P. Morgan Healthcare Conference signals ongoing investor engagement, yet the lack of fresh public disclosures hints at a pause in communication. Management’s recent insider purchases may help anchor the stock during a turbulent period, but the true test will come from clinical trial results and regulatory approvals. Until those milestones materialize, the insider transactions provide a cautious yet optimistic sign that TG’s leadership remains committed to long‑term value creation.